Solabia-Algatech Nutrition introduced a multi-blend AstaPure Max, which is centered around its Astapure Arava whole-algae astaxanthin complex, designed to reduce post-exercise muscle pain and fatigue.
Solabia-Algatech Nutrition (Kibbutz Ketura, Israel) introduced a multi-blend AstaPure Max, which is centered around its Astapure Arava whole-algae astaxanthin complex, designed to reduce post-exercise muscle pain and fatigue. The new blend is combined with easily-absorbed magnesium glycerophosphate and vitamin B6 (pyridoxine).
“Astaxanthin is increasingly gaining recognition both by industry stakeholders and health-conscious consumers for its valuable contribution to the sports nutrition sector,” said Doron Safrai, CEO of Solabia-Algatech Nutrition, in a press release. “As a world leading manufacturer of astaxanthin, our goal is to keep bringing astaxanthin-centered innovation to the market. That is why we developed the AstaPure Max formula uniquely for the flourishing sports nutrition category.”
The formula’s positive effect on physical resilience was demonstrated in an eight-week survey study conducted by the company. It compared AstaPure Max to a placebo on 160 subjects who exercise regularly at least three times a week. Over the eight-week period, 160 subjects were instructed to complete an online survey twice a week to monitor their experience, level of pain, cramps, and recovery. The AstaPure Max treatment group showed a substantial reduction in the number of subjects reporting pain, compared to a mild reduction in the placebo group. The group also reported a reduction in pain after exercise. At baseline, 74% experienced pain after exercise which was reduced to 47% after seven weeks, and35% after eight weeks of supplementation. These results were statistically different from the results of the placebo group in which 65% reported pain after exercise, which did not change after sever weeks, and only fell to 58% after eight weeks.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.